Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206648 · ClinicalTrials.gov registry record · Phase 4
An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS
A Phase 4 study of Multiple Sclerosis (Relapsing Remitting), sponsored by Bayer.
- Completed
- Registry status
- Phase 4
- Development phase
- 271
- Enrollment target
- 20
- Study locations
NCT00206648: Completed Phase 4 study of Multiple Sclerosis (Relapsing Remitting), sponsored by Bayer.
NCT00206648 is a Phase 4 study of Multiple Sclerosis (Relapsing Remitting) that has completed, run by Bayer. The registered enrollment target is 271 participants, below the 553-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00206648, a Phase 4 study of Multiple Sclerosis (Relapsing Remitting), has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 271 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the difference in preventing a relapse between Betaseron and Avonex. Patients with RRMS currently treated with Avonex will be randomized into 2 equal-size arms; one arm will continue on the standard dose of Avonex; one arm will be converted to Betaseron standard dose.
Conditions Studied
Interventions
- DRUG Betaferon/Betaseron
Study Locations (20)
California
- - Berkeley
- - Irvine
- - Loma Linda
- - Los Angeles
- - Sacramento
- - San Jose
- - Walnut Creek
- - Walnut Creek
Florida
- - Melbourne
- - Miami
- - Tampa
- - Tampa
Georgia
- - Atlanta
- - Augusta
- - Columbus
- - Savannah
Illinois
- - Flossmoor
- - Springfield
Arizona
- - Tucson
Delaware
- - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 271 participants |
| Start Date | 2003-03 |
| Est. Completion | 2005-10 |
| Phase | Phase 4 |
What the finished NCT00206648 record still lists
NCT00206648 is an interventional study that assigns participants to a tested intervention. The registered 271 participants enrollment target is mid-sized for trials with a published cap, below the 553-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Multiple Sclerosis (Relapsing Remitting) appearing as the primary indexed condition, and to 1 intervention - of which Betaferon/Betaseron is the first listed.
NCT00206648 names 20 study sites across 6 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT00206648 about?
NCT00206648 is a clinical study titled "An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS". The purpose of this study is to determine the difference in preventing a relapse between Betaseron and Avonex. Patients with RRMS currently treated with Avonex will be randomized into 2 equal-size arms; one arm will continue on the standard dose of Avonex; one arm will be converted to Betaseron stan...
What is the current status of trial NCT00206648?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 271 participants. The study started on 2003-03. Estimated completion is 2005-10.
What conditions does trial NCT00206648 study?
This clinical trial studies the following conditions: Multiple Sclerosis (Relapsing Remitting).
What interventions are being tested in trial NCT00206648?
The interventions under investigation include: Betaferon/Betaseron (DRUG).
Who is sponsoring clinical trial NCT00206648?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00206648 being conducted?
This trial has 20 study locations across Arizona, California, Delaware, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis (Relapsing Remitting)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00206648's enrollment target sits among peer trials
271 8th of 29 higher than 22 of 29 other Multiple Sclerosis (Relapsing Remitting) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis (Relapsing Remitting) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis
RECRUITING · Phase 4
-
Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS
ACTIVE NOT RECRUITING · Phase 4
-
Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis
RECRUITING · NA
-
Intermittent Hypoxia in Persons With Multiple Sclerosis
RECRUITING · NA
-
Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation
RECRUITING · NA
-
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03609216 · 271 participants · Phase 2
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations
- NCT02468024 · 272 participants · Phase 3
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
- NCT05519449 · 272 participants · Phase 1
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- NCT06035939 · 272 participants · NA
SMYLS Multi-site Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia